Abstract:
Disclosed is a biomarker of which gene expression levels are specifically increased or reduced for sensitive skin. The biomarker specific to sensitive skin is used in such a diagnostic kit for sensitive skin and a screening method of an abirritant. The biomarker for diagnosis of sensitive skin according to the present invention contains one or more gene selected from a group consisting of HLA-C, TCEA1, IGHA1, TFRC, S100A8, LOC652128, SERPINB13, EHF, FLJ10781, TP63, CDH1, TNFRSF19, GM2A, FKBP5, PI3, PSPH, HORMAD1, SPRR2G, and ACTR2 or a group consiting of KBTBD10, TTN, ACTA1, MYBPC1, MB, MYOZ1, TPM1, CA3, CASQ1, ENO3, RBP4, GYG2, PPP1R1A, PYGM, G0S2, NEB, H19, LIPE, PLIN, H19, GPAM, FABP4, CIDEC, LPL, PCK1, ADIPOQ, PDE3B, ACVR1C, LPL, FABP4, DKFZP761N09121, TNMD, ATP6V1B1, C8orf22, and CRISP3.
Abstract:
PURPOSE: A composition for preventing or treating alopecia caused by anticancer therapy and a method for preventing or treating alopecia are provided to reduce hair follicle dystrophy and the generation of side effects, to promote primary hair recovery, and to maximize therapeutic effects by preventing and/or suppressing alopecia caused by side effects when the composition is used with anticancer therapy. CONSTITUTION: A pharmaceutical composition for preventing or treating alopecia due to chemotherapy and radiotherapy for anticancer contains one or more telogen and/or catagen inducers. The telogen or catagen inducer is selected from a group consisted of epidermal growth factor (EGF), tumor necrosis factor (TGF-beta), dexamethasone, lipid peroxide, interferon-gamma, retinoic acid, and E2 (estrogen). A method for preventing or treating alopecia caused by chemotherapy and radiotherapy for anticancer comprises the step of topically administering the one or more telogen and/or catagen inducers on patient's scalp. A method for preventing or treating alopecia caused by chemotherapy and radiotherapy for anticancer is induction of hair cell growth cycle to telogen and/or catagen.